Skip to main content

Table 2 Baseline characteristics of study population

From: Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial)

Baseline variables Total population# (n = 882) Group A (Atorvastatin) (n = 221) Group B (Aspirin) (n = 221) Group C (Both) (n = 221) Group D (None) (n = 219)
Age (years) 52 (46–59) 51 (45–59) 53 (46–60) 52 (46–57) 52 (46–60)
Sex–Male 650 (74) 166 (75) 160 (72) 163 (74) 161 (74)
Number of days since symptom onset 6 (4–8) 6 (3–8) 6 (4–8) 6 (4–9) 5 (4–8)
Comorbidities
 Diabetes 244 (28) 65 (29) 57 (26) 69 (31) 53 (24)
 Hypertension 252 (29) 66 (30) 65 (29) 62 (28) 59 (27)
 Coronary artery disease 10 (1) 2 (1) 2 (1) 4 (2) 2 (1)
 Liver dysfunction 5 (1) 2 (1) 2 (1) 1 (0) 0 (0)
 Chronic kidney disease 21 (2) 5 (2) 5 (2) 4 (2) 7 (3)
Symptoms
 Fever 572 (65) 149 (67) 136 (62) 147 (67) 140 (64)
 Cough 496 (56) 122 (55) 119 (54) 127 (58) 128 (58)
 Shortness of breath 256 (29) 58 (26) 66 (30) 76 (34) 56 (26)
 Desaturation 82 (9) 16 (7) 18 (8) 28 (13) 20 (9)
 Body ache 94 (11) 29 (13) 22 (10) 21 (10) 22 (10)
 G I symptoms 85 (10) 20 (9) 24 (11) 21 (10) 20 (9)
 Loss of smell 31 (4) 7 (3) 7 (3) 6 (3) 11 (5)
 Loss of taste 49 (6) 11 (5) 12 (6) 13 (6) 13 (6)
Treatment received
 Hydroxychloroquine 87 (10) 29 (13) 18 (8) 19 (9) 21 (10)
 Azithromycin 103 (12) 31 (14) 23 (10) 26 (12) 23 (11)
 Remdesivir 182 (21) 39 (18) 51 (23) 51 (23) 41 (19)
 Favipiravir 38 (4) 11 (5) 10 (5) 7 (3) 10 (5)
 Doxycycline 177 (20) 48 (22) 48 (22) 36 (16) 45 (21)
 Anticoagulation 247 (28) 66 (30) 64 (29) 63 (29) 54 (25)
 Plasma therapy 2 (0) 0 (0) 0 (0) 1 (0) 1 (1)
 Tocilizumab 5 (1) 1 (0) 1 (0) 2 (1) 1 (1)
 Steroid 241 (27) 58 (26) 65 (29) 58 (26) 60 (27)
Baseline ordinal scale
 3 724 (82) 181 (82) 182 (82) 178 (81) 183 (84)
 4 133 (15) 33 (15) 33 (15) 37 (17) 30 (14)
 5 25 (3) 7 (3) 6 (3) 6 (3) 6 (3)
Blood investigations
 Hemoglobin (g/dL) 13 (11.7–14.3) 13.1 (11.8–14.3) 12.9 (11.7–14.4) 13.1 (12–14.3) 12.9 (11.6–14.2)
 TLC (/μL) 5905 (4540 -7 710) 5670 (4530–7510) 5920 (4600–7670) 5890 (4480–7860) 6020 (4600–8000)
 Platelet (× 103 /μL) 200 (149–258) 203 (156–262) 210 (151–261) 196 (149–254) 187 (141–262)
 Urea (mg/dL) 27 (21.4–36.4) 25.7 (21–36.4) 25.7 (21.4–36) 27.00 (21–36.4) 28.50 (22–38.5)
 Creatinine (mg/dL) 0.8 (0.7–0.9) 0.8 (0.7–0.9) 0.8 (0.7–0.9) 0.8 (0.7–0.9) 0.8 (0.7–0.9)
 Total Bilirubin (mg/dL) 0.5 (0.4–0.7) 0.5 (0.4–0.7) 0.5 (0.4–0.7) 0.5 (0.4–0.7) 0.5 (0.4–0.8)
 SGOT (IU/L) 38 (28.4–55) 37 (27.7–53) 41 (29–56) 38 (29–54.2) 36 (29–54)
 SGPT (IU/L) 39 (25.5–60) 38 (24–57.2) 39.9 (27–61) 39 (26.5–59) 39 (25–60)
 ALP (IU) 83 (67–108) 80 (65–110) 83 (20–109) 85 (67–108) 85 (69–104)
 Ferritin (ng/mL) 220.6 (106–506) 202 (97.9–436) 249.85 (121–493.9) 225.5 (109–538.4) 220.5 (105.9–571.3)
 D-Dimer (ng/mL) 153 (84–271) 138 (84–244) 159 (83–256) 152 (87–299) 168 (85–284)
 PT (sec) 12.2 (11.5–13) 12.3 (11.5–13.1) 12.3 (11.6–13.2) 12.1 (11.45–12.9) 12.1 (11.5–13)
 INR 1.1 (1–1.1) 1.1 (1–1.1) 1.1 (1–1.1) 1.1 (1–1.11) 1 (1–1.1)
 CRP (mg/dl) 1.4 (0.3–5.8) 1.4 (0.3–5.3) 1.5 (0.3–7) 1.2 (0.3–6.3) 1.2 (0.3–4.9)
 IL-6 (pg/mL) 6 (1.8–22) 6.8 (2–25.4) 5.5 (1.8–22) 7.9 (2–28.6) 5.2 (1.4–14.7)
 Trop I (ng/mL) 0.005 (0.001–0.008) 0.006 (0.001–0.007) 0.004 (0.001–0.008) 0.005 (0.001–0.008) 0.005 (0.001–0.008)
 CPK (IU/L) 96 (57–170) 92.50 (56–190) 98 (53–176) 97 (62–154) 97.50 (54–162)
  1. Values are median (p25–p75) or n (%)
  2. Local lab ranges: CRP ≤ 0.06 mg/dl, IL6 = 0–4.4 pg/ml, Ferritin = 22–322 ng/ml, D-dimer ≤ 500 ng/ml, CPK = 32–294 IU/L and Troponin I ≤ 0.04 ng/ml
  3. SD = standard deviation, GI = gastrointestinal, TLC = total leucocyte count, SGOT = serum glutamic-oxaloacetic transaminase, SGPT = serum glutamic pyruvic transaminase, ALP = alkaline phosphatase, PT = prothrombin time, INR = international normalized ratio, CPK = creatine phosphokinase, CRP = C-reactive protein, IL-6 = interleukin 6, Trop I = troponin I, IU = International Unit, L = litre, mL = millilitre, mg = milligram, pg = picogram, ng = nanogram
  4. #Modified intension-to-treat analysis